Dihydrostreptomycin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Dihydrostreptomycin
Accession Number
DB11512
Type
Small Molecule
Groups
Investigational, Vet approved
Description

Dihydrostreptomycin is an antibiotic.

Structure
Thumb
Synonyms
  • DHMS
  • DST
  • N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-a-L-glucopyranosyl]-3-C-(hydroxymethyl)-a-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine
  • N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-(hydroxymethyl)-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine
  • N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-α-L-glucopyranosyl]-3-C-(hydroxymethyl)-α-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine
Product Ingredients
IngredientUNIICASInChI Key
Dihydrostreptomycin sulfateT7D4876IUE5490-27-7Not applicable
Categories
UNII
P2I6R8W6UA
CAS number
128-46-1
Weight
Average: 583.596
Monoisotopic: 583.281319788
Chemical Formula
C21H41N7O12
InChI Key
ASXBYYWOLISCLQ-HZYVHMACSA-N
InChI
InChI=1S/C21H41N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h5-18,26,29-36H,3-4H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1
IUPAC Name
N-[(1R,2R,3S,4R,5R,6S)-3-carbamimidamido-4-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy}-2,5,6-trihydroxycyclohexyl]guanidine
SMILES
CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
AceclofenacAceclofenac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
AcemetacinAcemetacin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Experimental, Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Dihydrostreptomycin.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Dihydrostreptomycin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Withdrawn
AlcuroniumDihydrostreptomycin may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidDihydrostreptomycin may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Amdinocillin.Investigational, Withdrawn
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Dihydrostreptomycin.Approved, Investigational, Vet Approved
AmoxicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Dihydrostreptomycin.Approved, Investigational
AmpicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
ApocyninApocynin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumDihydrostreptomycin may increase the respiratory depressant activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateDihydrostreptomycin may increase the respiratory depressant activities of Atracurium besylate.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Dihydrostreptomycin.Approved, Vet Approved
AzapropazoneAzapropazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Azlocillin.Approved
AzosemideThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Azosemide.Investigational
BacampicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Bacampicillin.Approved, Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Dihydrostreptomycin is combined with Bacitracin.Approved, Vet Approved
BalsalazideBalsalazide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Dihydrostreptomycin.Investigational
BendazacBendazac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Dihydrostreptomycin.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Dihydrostreptomycin.Approved, Illicit
BenzydamineBenzydamine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Dihydrostreptomycin.Approved
BenzylpenicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevoniumBevonium may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
Botulinum Toxin Type ADihydrostreptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BDihydrostreptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved, Investigational
BromfenacBromfenac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Dihydrostreptomycin.Approved
BucillamineBucillamine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Experimental
BumadizoneBumadizone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
BumetanideThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Bumetanide.Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Dihydrostreptomycin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Dihydrostreptomycin.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dihydrostreptomycin.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental, Investigational
CarbenicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Carbenicillin.Approved, Investigational
Carbenicillin indanylThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Carbenicillin indanyl.Approved, Investigational
CarboplatinDihydrostreptomycin may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
CefaclorCefaclor may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
CefamandoleCefamandole may increase the nephrotoxic activities of Dihydrostreptomycin.Approved, Investigational
CefbuperazoneCefbuperazone may increase the nephrotoxic activities of Dihydrostreptomycin.Experimental
CefcapeneCefcapene may increase the nephrotoxic activities of Dihydrostreptomycin.Experimental
CefdinirCefdinir may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
CefditorenCefditoren may increase the nephrotoxic activities of Dihydrostreptomycin.Approved, Investigational
CefepimeCefepime may increase the nephrotoxic activities of Dihydrostreptomycin.Approved, Investigational
CefetametCefetamet may increase the nephrotoxic activities of Dihydrostreptomycin.Experimental
CefiximeCefixime may increase the nephrotoxic activities of Dihydrostreptomycin.Approved, Investigational
CefmenoximeCefmenoxime may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
CefmetazoleCefmetazole may increase the nephrotoxic activities of Dihydrostreptomycin.Approved, Investigational
CefminoxCefminox may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
CefodizimeCefodizime may increase the nephrotoxic activities of Dihydrostreptomycin.Experimental
CefonicidCefonicid may increase the nephrotoxic activities of Dihydrostreptomycin.Approved, Investigational
CefoperazoneCefoperazone may increase the nephrotoxic activities of Dihydrostreptomycin.Approved, Investigational
CeforanideCeforanide may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
CefotaximeCefotaxime may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
CefotetanCefotetan may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
CefotiamCefotiam may increase the nephrotoxic activities of Dihydrostreptomycin.Approved, Investigational
CefoxitinCefoxitin may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
CefozopranCefozopran may increase the nephrotoxic activities of Dihydrostreptomycin.Experimental
CefpiramideCefpiramide may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
CefpiromeCefpirome may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
CefpodoximeCefpodoxime may increase the nephrotoxic activities of Dihydrostreptomycin.Approved, Vet Approved
CefprozilCefprozil may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
CefsulodinCefsulodin may increase the nephrotoxic activities of Dihydrostreptomycin.Experimental
CeftazidimeCeftazidime may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
CeftibutenCeftibuten may increase the nephrotoxic activities of Dihydrostreptomycin.Approved, Investigational
CeftizoximeCeftizoxime may increase the nephrotoxic activities of Dihydrostreptomycin.Approved, Investigational
CeftriaxoneCeftriaxone may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
CefuroximeCefuroxime may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
CelecoxibCelecoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dihydrostreptomycin.Approved
ChloroquineChloroquine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dihydrostreptomycin.Approved
ChlorthalidoneThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Chlorthalidone.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
CisatracuriumDihydrostreptomycin may increase the respiratory depressant activities of Cisatracurium.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Dihydrostreptomycin.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Dihydrostreptomycin.Approved, Vet Approved
Clodronic AcidDihydrostreptomycin may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Cloxacillin.Approved, Investigational, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dihydrostreptomycin.Approved, Illicit
ColistimethateDihydrostreptomycin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
CyclacillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Cyclacillin.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydrostreptomycin.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Dihydrostreptomycin.Experimental
DecamethoniumDihydrostreptomycin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Dihydrostreptomycin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Desvenlafaxine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dihydrostreptomycin.Approved
DiclofenacThe risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Dihydrostreptomycin.Approved, Vet Approved
DicloxacillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Dicloxacillin.Approved, Investigational, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Dihydrostreptomycin.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Dihydrostreptomycin.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Dihydrostreptomycin.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dihydrostreptomycin.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dihydrostreptomycin.Approved, Investigational
Domoic AcidDihydrostreptomycin may increase the respiratory depressant activities of Domoic Acid.Experimental
DotarizineThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Dotarizine.Investigational
DoxacuriumDihydrostreptomycin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydrostreptomycin.Approved, Vet Approved
DroxicamDroxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Withdrawn
DuvelisibDuvelisib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Dihydrostreptomycin.Approved, Investigational
EpicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
Etacrynic acidThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Etacrynic acid.Approved, Investigational
EtanerceptEtanercept may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
EthanolDihydrostreptomycin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthenzamideEthenzamide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dihydrostreptomycin.Approved
Etidronic acidDihydrostreptomycin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydrostreptomycin.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Nutraceutical
ExisulindExisulind may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydrostreptomycin.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Withdrawn
FlomoxefFlomoxef may increase the nephrotoxic activities of Dihydrostreptomycin.Investigational
FlucloxacillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Dihydrostreptomycin.Approved
FlunixinFlunixin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
FluoxetineThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Fluoxetine.Approved, Vet Approved
FlurbiprofenFlurbiprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dihydrostreptomycin.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dihydrostreptomycin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Fluvoxamine.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
FurosemideThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydrostreptomycin.Approved, Investigational
GallamineDihydrostreptomycin may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideDihydrostreptomycin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Dihydrostreptomycin.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dihydrostreptomycin.Approved, Investigational
HigenamineHigenamine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
HydrocodoneDihydrostreptomycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Hydroflumethiazide.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dihydrostreptomycin.Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Dihydrostreptomycin.Approved
IbandronateThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Dihydrostreptomycin is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Dihydrostreptomycin.Approved
IbuproxamIbuproxam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Withdrawn
IpratropiumThe therapeutic efficacy of Ipratropium can be decreased when used in combination with Dihydrostreptomycin.Approved
IsoxicamIsoxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Vet Approved
KetorolacThe risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Dihydrostreptomycin.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dihydrostreptomycin.Approved, Investigational
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Dihydrostreptomycin.Experimental
LatamoxefLatamoxef may increase the nephrotoxic activities of Dihydrostreptomycin.Approved, Investigational
LeflunomideLeflunomide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dihydrostreptomycin.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Dihydrostreptomycin.Approved
LisofyllineLisofylline may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
LoracarbefLoracarbef may increase the nephrotoxic activities of Dihydrostreptomycin.Investigational, Withdrawn
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dihydrostreptomycin.Approved, Investigational
LornoxicamLornoxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
LoxoprofenLoxoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
LumiracoxibLumiracoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Magnesium hydroxide.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
Magnesium sulfateThe therapeutic efficacy of Dihydrostreptomycin can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Magnesium Trisilicate.Approved
MannitolMannitol may increase the nephrotoxic activities of Dihydrostreptomycin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
MecamylamineDihydrostreptomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Dihydrostreptomycin.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
MetampicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Metampicillin.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dihydrostreptomycin.Approved
MethyclothiazideThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Methyclothiazide.Approved
MeticillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Meticillin.Approved, Investigational
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Dihydrostreptomycin.Experimental
MetocurineDihydrostreptomycin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideDihydrostreptomycin may increase the respiratory depressant activities of Metocurine Iodide.Approved, Withdrawn
MezlocillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Mezlocillin.Approved, Investigational
MivacuriumDihydrostreptomycin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftifineNaftifine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
NaproxenThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Dihydrostreptomycin.Approved, Vet Approved
NeomycinThe risk or severity of adverse effects can be increased when Neomycin is combined with Dihydrostreptomycin.Approved, Vet Approved
NeosaxitoxinDihydrostreptomycin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Nicotine.Approved
NifenazoneNifenazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
NimesulideThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Dihydrostreptomycin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Dihydrostreptomycin.Experimental, Investigational
OlopatadineOlopatadine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dihydrostreptomycin.Approved
OrgoteinOrgotein may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Dihydrostreptomycin.Experimental, Investigational
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Dihydrostreptomycin.Approved
OxacillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Oxacillin.Approved, Investigational
OxaprozinOxaprozin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydrostreptomycin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydrostreptomycin.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Withdrawn
PalmidrolPalmidrol may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental, Nutraceutical
PamidronateDihydrostreptomycin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumDihydrostreptomycin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Dihydrostreptomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
PenamecillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Penamecillin.Experimental
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Dihydrostreptomycin.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Dihydrostreptomycin.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dihydrostreptomycin.Approved, Investigational
PhenoxymethylpenicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dihydrostreptomycin.Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
PipecuroniumDihydrostreptomycin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Piretanide.Approved
PirfenidonePirfenidone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
PiroxicamPiroxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Pivmecillinam.Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Polymyxin B Sulfate.Approved, Vet Approved
PramipexoleDihydrostreptomycin may increase the sedative activities of Pramipexole.Approved, Investigational
PranoprofenPranoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental, Investigational
PregabalinThe therapeutic efficacy of Dihydrostreptomycin can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
Procaine benzylpenicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dihydrostreptomycin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Dihydrostreptomycin.Approved, Investigational
PropacetamolPropacetamol may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
PropicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Dihydrostreptomycin.Experimental
PseudoephedrineThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Pseudoephedrine.Approved
PTC299PTC299 may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
PyrantelThe therapeutic efficacy of Pyrantel can be increased when used in combination with Dihydrostreptomycin.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydrostreptomycin.Approved
QuinethazoneThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Quinethazone.Approved
RapacuroniumDihydrostreptomycin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Experimental, Investigational
RisedronateDihydrostreptomycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Rizatriptan.Approved
RocuroniumDihydrostreptomycin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
RopiniroleDihydrostreptomycin may increase the sedative activities of Ropinirole.Approved, Investigational
SalicylamideSalicylamide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
Salicylic acidThe risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Dihydrostreptomycin.Approved, Investigational, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydrostreptomycin.Approved, Investigational
SemapimodSemapimod may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
SRT501SRT501 may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
SuccinylcholineDihydrostreptomycin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbenicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Dihydrostreptomycin.Approved
SulindacThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Dihydrostreptomycin.Approved, Investigational
SultamicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Sultamicillin.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Sumatriptan.Approved, Investigational
SuprofenSuprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
Technetium Tc-99m etidronateDihydrostreptomycin may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateDihydrostreptomycin may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
TetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Dihydrostreptomycin.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Dihydrostreptomycin.Investigational
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Ticarcillin.Approved, Investigational, Vet Approved
Tiludronic acidDihydrostreptomycin may increase the hypocalcemic activities of Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
Tolfenamic AcidThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Dihydrostreptomycin.Approved, Investigational
TolmetinTolmetin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Dihydrostreptomycin.Approved
TorasemideThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydrostreptomycin.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
TrichlormethiazideThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Trichlormethiazide.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Dihydrostreptomycin.Approved
TriptolideTriptolide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
Trolamine salicylateThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Dihydrostreptomycin.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Dihydrostreptomycin.Approved
TubocurarineDihydrostreptomycin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dihydrostreptomycin.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Dihydrostreptomycin.Approved
VecuroniumThe therapeutic efficacy of Vecuronium can be increased when used in combination with Dihydrostreptomycin.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Venlafaxine.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Dihydrostreptomycin.Investigational
ZaltoprofenZaltoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Dihydrostreptomycin.Approved
ZileutonZileuton may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Dihydrostreptomycin is combined with Zoledronic acid.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Zolmitriptan.Approved, Investigational
ZolpidemDihydrostreptomycin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracZomepirac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dihydrostreptomycin.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. CURCI G: [Dihydrostreptomycin]. Arch Tisiol Mal Appar Respir. 1951 Mar;6(3):Varia, 104-6. [PubMed:14830485]
  2. Midtvedt T: [Dihydrostreptomycin]. Tidsskr Nor Laegeforen. 1970 Apr 15;90(8):791. [PubMed:4194808]
  3. BARTZ QR, CONTROULIS J, et al.: Dihydrostreptomycin. J Am Chem Soc. 1946 Nov;68(11):2163-6. [PubMed:21002218]
  4. HARRISON WH: Dihydrostreptomycin deafness. Antibiot Annu. 1959-1960;7:549-51. [PubMed:14400056]
  5. SHAMBAUGH GE Jr, DERLACKI EL, HARRISON WH, HOUSE H, HOUSE W, HILDYARD V, SCHUKNECHT H, SHEA JJ: Dihydrostreptomycin deafness. J Am Med Assoc. 1959 Aug 1;170(14):1657-60. [PubMed:13672753]
  6. MAHADY SC, ARMSTRONG FL, MONROE J: Purified dihydrostreptomycin. Am Rev Tuberc. 1956 May;73(5):776-8. [PubMed:13313964]
  7. AGOPSOWICZ G, BEKIERKUNST A, HOCHBERGER B, JEDRZEJEWSKA A, KOSSOWSKI S: [Dihydrostreptomycin and dihydrostreptomycin-penicillin therapy of ozena]. Arch Immunol Ther Exp (Warsz). 1955;3:239-47. [PubMed:13395829]
  8. LEES JK, MARKLE DM: Dihydrostreptomycin and deafness. N Y State J Med. 1953 Dec 15;53(24):2997-9. [PubMed:13111505]
  9. Authors unspecified: [Dihydrostreptomycin in pulmonary tuberculosis]. Dia Med. 1951 Sep 24;23(64):2861; passim. [PubMed:14879647]
  10. SHANE SJ, LAURIE JH: Neurotoxicity of dihydrostreptomycin. Can Med Assoc J. 1950 Sep;63(3):277-9. [PubMed:15434767]
External Links
KEGG Drug
D07840
KEGG Compound
C01023
ChemSpider
388489
ChEBI
38291
ChEMBL
CHEMBL1950576
HET
71R
Wikipedia
Dihydrostreptomycin
ATC Codes
S01AA15 — Dihydrostreptomycin
PDB Entries
5lpa

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentBMI >30 kg/m2 / Metabolic Syndromes1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility16.0 mg/mLALOGPS
logP-3ALOGPS
logP-7.3ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)12.11ChemAxon
pKa (Strongest Basic)11.31ChemAxon
Physiological Charge3ChemAxon
Hydrogen Acceptor Count19ChemAxon
Hydrogen Donor Count15ChemAxon
Polar Surface Area334.59 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity150.45 m3·mol-1ChemAxon
Polarizability56.06 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0001090000-e5c939b16a98cbc76e8f
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0001090000-f492efdcf9b73dccff78
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0110090000-a21d136fb6ad87c99c54
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03di-1290020000-c272561234831b3053da
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03ka-1190000000-4c31681402bf294549fd
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-0090000000-094483dbe63a6b4a3a35
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0bvi-3940300000-adca1fa480c33dd8c023
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-01w1-9570000000-da64f1603c2c8b791414
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0fki-9340000000-915a5b4c2e2c08346763
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0fgx-9010000000-0d0be639d3cdcb114f75
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-03di-0090010000-2014c0916e72e16177f4

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidically linked to a carbohydrate moiety. There are two major classes of aminoglycosides containing a 2-streptamine core. They are called 4,5- and 4,6-disubstituted 2-deoxystreptamines.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminocyclitol glycosides
Alternative Parents
O-glycosyl compounds / Cyclohexanols / Oxanes / Monosaccharides / Cyclitols and derivatives / Tetrahydrofurans / Tertiary alcohols / Guanidines / 1,2-aminoalcohols / Propargyl-type 1,3-dipolar organic compounds
show 8 more
Substituents
Amino cyclitol glycoside / Glycosyl compound / O-glycosyl compound / Cyclohexanol / Cyclitol or derivatives / Monosaccharide / Oxane / Cyclic alcohol / Tertiary alcohol / Tetrahydrofuran
show 20 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
streptomycins (CHEBI:38291)

Drug created on February 26, 2016 10:29 / Updated on August 02, 2018 07:56